

Sareum Holdings PLC

("Sareum" or the "Company")

Notice of Interim Results for the Year Ended 31 December 2025 and Investor Presentation

Cambridge, UK, 3 March 2026- Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, will announce its unaudited financial results for the six months ended 31 December 2025 on Thursday, 12 March 2026.

The Company will also be holding a live presentation to investors on Thursday, 12 March 2026 at 14:00 GMT via the Investor Meet Company platform.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 11 March 2026, 09:00 GMT, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet SAREUM HOLDINGS PLC via: <https://www.investormeetcompany.com/sareum-holdings-plc/register-investor>

Investors who already follow SAREUM HOLDINGS PLC on the Investor Meet Company platform will automatically be invited.

A copy of the presentation will be made available on the Company's website following the presentation.

- Ends -

For further information:

Sareum Holdings plc

Stephen Parker, Executive Chairman

01223 497700

ir@sareum.co.uk

Strand Hanson Limited (Nominated Adviser)

James Dance / James Bellman

020 7409 3494

Singer Capital Markets (Joint Corporate Broker)

Phil Davies

020 7496 3000

Oberon Capital (Joint Corporate Broker)

Mike Seabrook / Nick Lovering

020 3179 5300

ICR Healthcare (Financial PR)

Jessica Hodgson / Davide Salvi

020 3709 5700

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with a planned initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for certain haematological cancers and has recently initiated a preclinical programme to develop TYK2/JAK1 inhibitors for neuroinflammatory diseases such as multiple sclerosis and Parkinson's disease

The Company has recently acquired the license for SRA737, a clinical-stage Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORAKBBDONK